VA-REGULA
5.6.2024 08:31:32 CEST | Business Wire | Press release
Access to international festivals like Sziget and Untold, which draw up to 100,000 visitors daily, has been significantly enhanced. Regula, a global developer of forensic devices and identity verification solutions, and Netpositive, a Hungarian IT service provider specializing in large-scale event management, joined forces to switch to mobile ID verification (IDV) via a special app empowered by IDV software. As a result, Netpositive’s state-of-the-art Backstage Ticketing ecosystem has become an even more valuable asset for event organizers across the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604833546/en/
Netpositive’s new Backstage Ticketing solution for large events’ visitor ID verification based on Regula Document Reader SDK (Graphic: Business Wire)
The backbone of access services to large-scale events is the so-called “redemption” process, during which visitor tickets are checked and exchanged for wristbands with designated access rights. For this process to function properly, it is necessary to identify event visitors by their identity documents.
Netpositive used to handle document verification with the help of designated ID scanners provided by a third-party vendor. Apart from that, the company also employed a range of other devices, such as barcode readers, NFC readers, and laptops. The complexity of managing these devices often led to inefficiencies at event redemption points.
To make the process more productive and streamlined, Netpositive decided to switch to mobile ID verification (IDV) via a special app empowered by IDV software. After performing extensive research and following a partner’s recommendation, Netpositive opted for Regula Document Reader SDK, a comprehensive identity document verification software solution. Within one month, Regula’s solution was seamlessly built into Netpositive’s Backstage Ticketing Access Management App and integrated into their larger ecosystem, where they manage everything from ticket sales to redemption checks to event dashboards.
Regula Document Reader SDK allows Netpositive’s Backstage Ticketing ecosystem to read and verify passports, ID cards, and driver’s licenses with a single mobile device. Not only does Regula’s solution speed up the document check process, but it also enhances security by performing cross-checks to identify any data discrepancies that could indicate fraud. Apart from that, Regula Document Reader SDK re-verifies biometric documents on the server side in the customer’s secure perimeter in order to ensure that the chip is genuine and its data has not been cloned or manipulated, and thus prevent sophisticated fraud. The solution's extensive document template database includes over 13,900 templates from 249 countries and territories, ensuring comprehensive coverage and seamless processing for international event attendees.
Implementing Regula’s technology has already shown remarkable success at recent events, such as Untold Dubai, visited by over 185,000 people, and Massif in Romania, with a capacity of 12,000 people per day. The streamlined mobile solution has reduced queues, cut down manual labor, and received overwhelmingly positive feedback from staff and attendees alike.
In the long run, Netpositive expects to cut expenses on device procurement, and expects to significantly reduce the number of technical problems involved with the redemption process, which were relatively frequent with the previous solution.
“We are still at an early stage of the access admission process transformation, and we assume we will get more tangible results during the coming season of summer festivals. But we are very sure of one thing: with this new solution with the Regula Document Reader SDK at the core, we made a real innovation. The reinvention of the redemption process helped us become more competitive, promoting our position in the market,” says Mátyás Török, Netpositive’s founder and CEO.
"Our collaboration with Netpositive not only showcases the importance of robust and efficient identity verification, but also sets a new standard for access management in large-scale events. We are proud to contribute to creating safer and more efficient event experiences around the globe," says Ihar Kliashchou, Chief Technology Officer at Regula.
For more information on how Netpositive is transforming event access management with Regula’s IDV solutions, read the success story.
About Netpositive
Netpositive creates large-scale, unique, load-proof digital solutions. With more than 50 partners, 500 international events, and 36 million unique users, it became Central Europe's leading event IT service provider during the last 10 years. You can meet its staff and its self-developed Backstage Ticketing ecosystem at several domestic and international events, including award-winning music festivals like Sziget (HU) and Untold (RO).
Learn more at www.netpositive.hu.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604833546/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
